A recent Brazilian clinical trial, published in the Journal of Alzheimer’s Disease and widely reported in December 2025, marks a groundbreaking development in exploring cannabis for Alzheimer’s treatment.
Researchers at the Federal University of Latin American Integration conducted a phase 2, randomized, double-blind, placebo-controlled study involving elderly patients aged 60-80 with mild Alzheimer’s disease.
Building on prior animal studies showing low-dose THC restoring cognition in aged mice and a 2022 case report where microdosing improved symptoms in one patient over 22 months, this trial tested daily oral microdoses of a balanced cannabis extract containing approximately 0.3 mg THC and 0.3 mg CBD—far below psychoactive levels.
Over 24-26 weeks, the treatment group showed stabilized cognitive function, as measured by the Mini-Mental State Examination (MMSE), while the placebo group experienced typical decline.
This pausing of progression represents the first human trial evidence of microdosing cannabinoids potentially halting Alzheimer’s-related cognitive deterioration without significant side effects.
Described as unprecedented, the approach leverages the endocannabinoid system’s role in neuroprotection, which naturally diminishes with age. Though promising, the study’s small sample size and limited scope to certain cognitive metrics highlight the need for larger, longer trials to confirm efficacy and safety.
Current Alzheimer’s therapies offer minimal benefit and often severe side effects, making this low-risk cannabinoid option a hopeful avenue amid rising dementia cases globally.
#scienceacumen
#facebookrepost
